Navigation Links
Vanderbilt-Ingram Cancer Center launches online genetic research tool
Date:3/4/2011

Vanderbilt-Ingram Cancer Center (VICC) has launched the nation's first personalized cancer decision support tool, "My Cancer Genome," to help physicians and researchers track the latest developments in personalized cancer medicine and connect with clinical research trials for their patients.

This web-based information tool (www.MyCancerGenome.org) is designed to quickly educate clinicians on the rapidly expanding list of genetic mutations that impact different cancers and, at the same time, enable them to more easily research various treatment options based on specific mutations.

My Cancer Genome is the latest addition to VICC's Personalized Cancer Medicine Initiative, which was unveiled last year.

"Next-generation, or genetically-informed cancer medicine, holds the promise of tailoring anti-cancer treatment according to individual patient tumor characteristics," said William Pao, M.D., Ph.D., associate professor of Medicine and director of Personalized Cancer Medicine at VICC.

"Staying abreast of these fast-paced research changes may be difficult for time-pressed oncologists and medical caregivers. In particular, knowledge about rare variants found in cancers may be hard to track down, especially in busy clinics. We launched this web-based tool to enable a genetically-informed approach to cancer medicine that we believe can be more efficient and effective."

With just a few clicks, users can get up-to-date information on the clinical significance of specific mutations.

Here's how it works: A doctor receives tumor profiling results from the lab that show a mutation in a specific gene. The doctor remembers a little about the gene, but hasn't seen that result very often, as it is relatively uncommon.

Instead of having to search through a great deal of literature, the physician can log on to VICC's My Cancer Genome tool and, within a few minutes, find the latest information about the clinical implications of the gene, either by reading the summary version or delving further into the primary literature through web links. The physician can then recommend treatment that is currently available or refer the patient to a clinical trial that is testing a targeted therapy for that gene.

Finally, the patient also can go to the VICC website and learn more about their cancer by using the My Cancer Genome tool.

"We designed this online tool to be comprehensive, scalable and easy for clinicians to use," said Mia Levy, M.D., Ph.D., assistant professor of Biomedical Informatics and Medicine and Cancer Clinical Informatics Officer for VICC.

"This new online tool is already linked to Vanderbilt University Medical Center's StarPanel electronic medical record database to help our physicians make treatment decisions quickly, based on the best science available.

"Once we test a patient's tumor for specific mutations, the test results stay in a patient's medical record, so as new treatment options become available for each mutation, our physicians will have that information at their fingertips," Levy said.

The first two forms of cancer featured on VICC's My Cancer Genome information tool are lung cancer and melanoma, with plans to add content on breast, colon and other cancers in a few months.

"We envision that VICC's My Cancer Genome can become a global research and resource platform connecting the entire cancer community, including doctors, researchers, students, patients and caregivers.

"We will be reaching out in the future to encourage all stakeholders to contribute information so that we can improve information flow and accelerate the development of better personalized targeted therapy for all cancer patients," Pao said.


'/>"/>

Contact: Dagny Stuart
dagny.stuart@vanderbilt.edu
615-936-7245
Vanderbilt University Medical Center
Source:Eurekalert

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
3. The dietary supplement genistein can undermine breast cancer treatment
4. Saliva proteins could help detection of oral cancer
5. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
6. Breakthrough optical technology to assess colon cancer risk, accuracy
7. Breast cancer cells recycle to escape death by hormonal therapy
8. Nanodiamond drug device could transform cancer treatment
9. Second lumpectomy for breast cancer reduces survival rates
10. Study looks at psychological impact of gene test for breast cancer
11. SNM releases new fact sheet on breast cancer and molecular imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/8/2016)... 8, 2016 Market Research Future published a half cooked ... Mobile Biometric Security and Service Market is expected to grow over ... Market Highlights: ... Mobile Biometric Security and Service ... increasing need of authentication and security from unwanted cyber threats. The ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... CLARA, Calif. , Jan. 24, 2017  Frost & Sullivan ... of the Fonar Corporation, will receive special recognition at the ... taking place March 19 to 21, 2017 at the Loews Coronado ... To register and download the event agenda for Medical ... www.frost.com/medtech ...
(Date:1/24/2017)... Pa. , Jan. 24, 2017   Bracket ... provider, today announced the addition of Jennifer Peters ... Senior Vice President and General Manager for the Scientific ... responsible for Bracket,s work in Rater Training, Quality Assurance, ... Bracket with a strong skillset and demonstrated record building ...
(Date:1/24/2017)... MONTREAL , Jan. 24, 2017 /PRNewswire/ - BioAmber Inc. ... demand, the underwriters have agreed to increase the size of ... stock of the Company, together with warrants to purchase 1,842,106 ... price of US$5.50 per share of common stock (the "Exercise ... share and associated warrant (the "Public Price"). The warrants have ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... label-free graphene biosensor assays for fragment-based screening, will showcase its proprietary ... Society for Laboratory Automation and Screening (SLAS) conference in Washington, D.C. from Feb. ...
Breaking Biology Technology: